Gracell Biotechnologies Inc. (NASDAQ:GRCL – Get Free Report) has received an average recommendation of “Hold” from the eight brokerages that are presently covering the company, Marketbeat reports. Five investment analysts have rated the stock with a hold recommendation and three have assigned a buy recommendation to the company. The average 1-year target price among brokerages […]

Related Keywords

Piper Sandler , Stifel Nicolaus , Venture Partners Investment Advisor , Wells Fargo Company , Nasdaq , Gracell Biotechnologies Inc , Sphera Funds Management , Vivo Capital , Gracell Biotechnologies , Get Free Report , Funds Management , Bay Capital Management , Get Free , Biotechnologies Inc , Gracell Biotechnologies Daily , Nasdaq Grcl , Grcl , Medical , Ratings , Consensus ,